Barrenjoey’s research department initiated on PYC Therapeutics last month in hopes of strengthening its relationship with the budding biotech. But the inhabitants of the Vertical Village only had to wait 24 hours for a deal to land.
It’s a whole team effort at Barrenjoey Capital Partners.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
